Download Files:
Products Details
Product Description
– Zharp2-1 is an oral effective RIPK2 inhibitor, highly associated with inflammatory bowel disease (IBD). Zharp2-1 blocker muramyl dipeptide (MDP) induces growth of mononuclear cells and induces inflammatory cell factor infection. Zharp2-1 attenuates MDP-induced small inguinal peritonitis, or ameliorates by DNBS-induced large inguinal conjunctivitis[1].
Web ID
– HY-155782
Shipping
– Room temperature
Molecular Formula
– C19H18N3O2PS
References
– [1]Lai Y, et al. Discovery of a novel RIPK2 inhibitor for the treatment of inflammatory bowel disease. Biochem Pharmacol. 2023 Aug;214:115647.
CAS Number
– 2772600-18-5
Molecular Weight
– 383.40
SMILES
– O=P(C)(C1=C(OC)C=C2N=CC=C(NC3=CC=C(SC=N4)C4=C3)C2=C1)C
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology
Solubility
– 10 mM in DMSO
Target
– RIP kinase
Pathway
– Apoptosis
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
